Big Pharma: Getting Too Big for Its Own Good?
A study by McKinsey & Co. earlier this year looked at the net present value of products out of research vs. the spending on R&D for the top pharma players over the last decade. It found no correlation between the return on investment and a company’s size
European Patent Office bars human cloning in patent
The European Patent Office added restrictions on Wednesday to a controversial patent granted in 1999 to prevent it being used to clone humans, a ruling limiting biotech research in Europe.
Woman carries human clone, group says
fringe religious movement’s South Korea-based scientific team yesterday said they had implanted a cloned human embryo in a woman, the latest of a string of similar uncomfirmed experiments to emerge from the underground field of human cloning.
Monoclonal Antibodies Look to a Bright Future
Using mAbs as therapeutics could cut preclinical development time by as much as two-thirds and cost by even greater levels.
Genomics Sector Has Fired More Than 1,500 Staff Since January 2001
The following is a general compilation of the number of employees at genomic tool and tech firms who have lost their jobs as the industry, bookended by slowdowns at biotech and pharma customers, struggles to stay afloat.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments